• Cytori Therapeutics Inc., of San Diego, entered a $15 million loan facility with GE Healthcare Financial Services and Silicon Valley Bank. That included an initial term loan of $7.5 million funded Oct. 14, and Cytori will be able to exercise the additional $7.5 million term loan on or before Dec. 12, provided it meets certain financial prerequisites established by the lenders. The funding will be used to support the commercialization of Cytori's recently launched Celution System and StemSource Cell Bank in Europe and Asia, as well as to support pipeline development and for general corporate purposes.

• Resverlogix Corp., of Calgary, Alberta, said it redeemed $10 million, or about 60 percent, of its remaining $17.3 million debenture. Under the terms, that redemption will consist of 2.4 million common shares with a value of $5.5 million plus $4.5 million cash. Along with the removal of future certain dilution factors, the company also gained the option to buy out any remaining debenture at a 25 percent premium. Shares of Resverlogix (TSX:RVX) fell 30 percent Wednesday to close at C$2.38 (US$2), down C$1.02.